Secondary outcomes
[용어속성] Term
Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: A systematic review
Article
[키워드] affected
all-cause mortality
Analysis
Care
clinical
Clinical outcome
country
COVID-19
COVID-19 cases
COVID-19 vaccination
database
dataset
death
deaths
determine
evaluated
facilitator
groups
Health
healthcare
high risk
hospitalisation
hospitalisations
Impact
impacts
increased risk
Infection
information
International
National
outcome
pandemic
peer-reviewed
Population
populations
Primary outcome
public health
reduced
reported
response
Result
risk factor
Risk factors
screened
searched
secondary outcome
Secondary outcomes
systematic review
[DOI] 10.1016/j.jmh.2021.100041 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.jmh.2021.100041 PMC 바로가기 [Article Type] Article
A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial
SARS-CoV-2 유발 급성 호흡곤란 증후군에 대한 정맥내 혈장 정제 알파-1 항트립신의 무작위 이중 맹검 위약 대조 파일럿 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 24 hours
active malignancy
acute kidney
Acute kidney injury
acute respiratory distress syndrome
addition
Administered
administration
adverse event
adverse events
AEs
age
Alpha
alpha-1 antitrypsin
Amendment
Anti-viral
Antibiotics
anticipated
antitrypsin
antivirals
approval
approved
ARDS
ARMS
authority
bacterial pneumonia
baseline
Berlin criteria
blinded to treatment
Blinding
BMI
body weight
Cancer
changes in
Child-Pugh score
chloride
Chronic kidney disease
chronic liver disease
circulating
class
clinical
Clinical outcome
clinical trial
Combination
commenced
Committee
comparator
Complete
conducted
Consent
Controlled trial
correction
COVID-19
Culture
cytokine level
cytokine levels
Data collection
defined
determine
Diagnosis
diagnosis of ARDS
dialysis
dissemination
DNAR
double-blind
Echocardiogram
Effect
Effectiveness
elapsed
element
ELISA
enrolled
EudraCT
excluded
exclusion
exclusion criteria
facilitate
Follow-up
followed by
for inclusion
group
Health Products regulatory Authority
hospital
Hospital admission
hypertension
ICU
IgA deficiency
IL-10
IL-1β
IL-6
IL-8
incidence
inclusion criteria
individual
information
intensive care unit
intensive care units
interim analysis
interleukin
interleukin-10
interleukin-1β
interleukin-6
interleukin-8
interpreter
Intervention
intravenous
intravenous infusion
intravenously
invasive
investigational medicinal product
investigator
Ireland
Kidney disease
Laboratory
laboratory-confirmed
life
Local
maintain
major trauma
malignancy
mandatory
marker
mechanical ventilation
Microscopy
moderate
moderate to severe
Mortality
Non-invasive
non-invasive mechanical ventilation
non-invasive ventilation
number
objective
occur
Organ failure
outcome
outcome measure
PaO
participant
Patient
patient recruitment
patients with moderate
PCR-confirmed
Phase 2
physician
Placebo
placebo-controlled
plasma
plasma analysis
plasma concentration
plasma concentrations
pregnant
preparation
product
protocol
provided
Pulmonary embolism
pulmonary hypertension
purified
Radiographic
randomisation
randomisation list
randomised
randomised controlled trial
rationale
readmission
REC
receiving
receptor
recruited
recruitment
reduce
Regulatory
removal
renal
renal replacement therapy
replacement therapy
reported
required
Research
Research Ethics
Research Ethics Committee
research nurse
research nurses
respiratory
respiratory distress
Respiratory distress syndrome
resulting
Resuscitation
SAE
SAEs
Sample size
SARS-CoV-2
secondary
secondary bacterial pneumonia
Secondary objective
Secondary objectives
Secondary outcomes
secretion
Sequential Organ Failure Assessment
Serious Adverse Event
Serious Adverse Events
severe ARDS
Shock
single dose
skin cancer
Sodium chloride
SOFA
Standard
statistician
stratified
study participation
Study protocol
subject
submitted
supplementary material
Support
sustained
TNF
TNF-α
Tolerability
trauma
Treatment
treatment allocation
Trial
trial protocol
Trial registration
vasopressors
ventilator
verbal
Version
Volume
website
WHO
Withdrawal
writing
[DOI] 10.1186/s13063-021-05254-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05254-0 PMC 바로가기 [Article Type] Letter
Impact of COVID-19 on the hospitalization, treatment, and outcomes of intracerebral and subarachnoid hemorrhage in the United States
Research Article
[키워드] adjusted odds ratio
base
Black patient
clinical
Cohort
cohorts of patient
Control
control patient
controls
COVID
COVID-19
COVID-19 infection
death
diabete
Diabetic
diagnosed
discharge
Hispanic patient
hospital
Hospital stay
Hospitalization
hospitals
ICH
Impact
In-hospital death
Infection
Intracerebral hemorrhage
logistic regression model
obese
obesity
objective
outcome
outcomes
Patient
performed
Primary outcome
proportion
Racial
Result
Retrospective analysis
Secondary outcomes
significantly higher
subarachnoid hemorrhage
the United State
Treatment
with COVID-19
[DOI] 10.1371/journal.pone.0248728 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0248728 PMC 바로가기 [Article Type] Research Article
Primary Care implementation of Germ Defence, a digital behaviour change intervention to improve household infection control during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial
COVID-19 전염병 동안 가정 감염 통제를 개선하기 위한 디지털 행동 변화 개입인 Germ Defence의 1차 진료 구현: 무작위 통제 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
antibiotic
Behaviour change
blinded
Blinding
block
blocks
Bristol
Care
clinical
Cluster
collaboration
Commission
comparator
Contact
Controlled trial
coronavirus
COVID-19
COVID-19 symptom
detect
diagnose
Digital health
Digital medicine
dissemination
Effect
effect size
Effectiveness
element
engage
England
enrolment
Gastrointestinal infection
gastrointestinal infections
general practices
Germ
group
hand washing
help
Hospital admission
hygiene
identity
implementation
IMPROVE
incidence
incidence of COVID-19
include
independent
individual
Infection
infection control
Infectious disease
Intervention
intervention arm
involved
ISRCTN
ISRCTN registry
management
measure
number
objective
outcome
overcome
participant
Patient
personalised
Prevalence
primary care
Primary outcome
Principal Investigators
problem
problem solving
protection
protocol
randomisation
randomised
randomised controlled trial
Randomly
receive
reduce
Registered
respiratory
respiratory tract infection
Sample size
secondary outcome
Secondary outcomes
Spread
Stata Statistical Software
statistical
statistician
Study protocol
supplementary material
Symptom
Trial
Trial registration
Two-arm
usual care
website
[DOI] 10.1186/s13063-021-05188-7 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05188-7 PMC 바로가기 [Article Type] Letter
Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial
아편유사제 사용 장애 치료에 대한 주사기 서비스 프로그램 기반 원격 의료 연결: STAMINA 무작위 대조군 시험을 위한 프로토콜
Study Protocol
[키워드] access
All participant
All participants
Analysis
approach
ARMS
baseline
Buprenorphine
center
change
Chicago
clinical
collected
Complete
conducted
control arm
COVID-19 pandemic
detect
disorder
Effect
engage
Epidemic
expand
Expanded access
Facilitating
generalized linear regression
health center
include
initial
initial assessment
Intervention
intervention arm
lead
linear regression analyses
medication
Medication assisted treatment
Medication for opioid use disorder
medications
Methadone
naltrexone
occurred
open
Open Science Framework
opioid
opioids
outcome
outcomes
overdose
participant
platform
Primary outcome
Probability
protocol
provided
Randomized
receive
recruit
reduce
Registered
Regulatory
retained
risk
Saliva
secondary
Secondary outcomes
service
significantly
STAMINA
Study protocol
Substance use disorder
survival
survival analysis
Syringe
Syringe exchange
telehealth
Telemedicine
telemedicine intervention
telemedicine interventions
Treatment
treatment initiation
Trial
Trial registration
[DOI] 10.1186/s12889-021-10669-0 PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.1186/s12889-021-10669-0 PMC 바로가기 [Article Type] Study Protocol
Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial
확인된 COVID-19 사례(CORIPREV)의 긴밀한 접촉에서 SARS-CoV-2에 대한 노출 후 예방: 클러스터 무작위 시험을 위한 연구 프로토콜
Study Protocol
[키워드] 1:1
adaptive
Analysis
approach
attack rate
baseline
Chain Reaction
Chemoprophylaxis
close contact
Cluster
Cluster randomization
Clusters
Combination
confirmed COVID-19 case
Confirmed COVID-19 infection
Contact
control arm
correlation coefficient
Course
COVID-19
COVID-19 infection
COVID-19 pandemic
defined
detect
Diseases
drug
early treatment
Efficacy
epidemiological
estimate
evaluate
excluded
exposure to
generalized linear mixed model
Hospitalization
ICC
include
incorporation
individual
Infection
Infectious diseases
Interim analyses
interim analysis
Intervention
intervention arm
life
linear mixed model
logit
Lopinavir
Lopinavir/ritonavir
medication
microbiologically
modify
Mortality
multicenter
novel
Open-label
oral lopinavir/ritonavir
outcome
participant
polymerase chain
polymerase chain reaction
positive
Post-exposure prophylaxis
Prevent
prevention
prevention approach
primary analysis
Primary outcome
Probability
Prophylaxis
protocol
psychological Impact
Quality of life
Randomized controlled trial
Registered
Relative risk
respiratory
Respiratory failure
respiratory tract
risk reduction
Ritonavir
Safe
Sample size
sample size calculation
SARS-CoV-2
secondary
secondary attack rate
Secondary outcomes
Seropositivity
specimen
Study protocol
study visit
subset
supplementary material
Support
switching
symptomatic
symptomatic COVID-19
Trial
Trial registration
ventilator
[DOI] 10.1186/s13063-021-05134-7 PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.1186/s13063-021-05134-7 PMC 바로가기 [Article Type] Study Protocol
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석이 포함된 살아있는 체계적인 검토의 두 번째 판(The LIVING 프로젝트)
Meta-Analysis
[키워드] 95% CI
95% confidence interval
adjusted
Admission
aggregate data meta-analyses
all age group
all age groups
all-cause mortality
Analysis
boundary
bromhexine
caused
certainty
certainty of evidence
Clinical research
Clinical significance
Cochrane guidelines
comparison
Comparisons
Corticosteroid
Corticosteroids
COVID-19
database
Effect
Effects
eight
events
Evidence
evidence of
Families
FIVE
Fixed-effect meta-analysis
futility
GRADE
high risk
Hydroxychloroquine
Immunoglobulin
indicate
indication
indications
individual patient data meta-analyses
individuals
information
intensive care
Intervention effects
intravenous
Intravenous immunoglobulin
lack
life
Lopinavir
Lopinavir-ritonavir
mechanical ventilation
meta-analyses
Meta-analysis
moderate
Network meta-analysis
no evidence of
non-serious adverse
non-serious adverse events
on mechanical ventilation
outcome
outcomes
participant
Participants
patient data
performed
Primary outcomes
PRISMA
Quality of life
random error
random errors
random-effects meta-analyses
randomized clinical trial
randomized clinical trials
rapidly spreading disease
reached
reduce
reduced
Remdesivir
renal replacement therapy
replacement therapy
required
Research
risk
risk of death
risk ratio
risks of bia
Ritonavir
searched
second
secondary
Secondary outcomes
sequential analysis
Serious Adverse Event
Serious Adverse Events
single trial
standard care
statistically significant
systematic review
threshold
Tocilizumab
Treatment
treatment for COVID-19
treatment intervention
treatments of COVID-19
Trial
Trial methodology
trial sequential analyses
trial sequential analysis
website
with COVID-19
[DOI] 10.1371/journal.pone.0248132 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pone.0248132 PMC 바로가기 [Article Type] Meta-Analysis
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
absence
acutely ill hospitalized medical patients
Admission
age
allergy
allocation concealment
allocation sequence
Alpha
America
and protocol
Anticoagulant
anticoagulation
antiplatelet
antithrombotic therapy
apixaban
arterial
bleeding
bleeding risk
Blinding
block sizes
blood cell
Brazil
can not
Canada
Care
Chain Reaction
changed
choice
clinical trial
clinically
clinician
Coagulation
Coagulopathy
Committee
complex
Composite
computer-generated
contraindication
control group
Controlled
COVID
COVID-19
Critical
Critical illness
cryoprecipitate
D-dimer
D-dimer value
Dabigatran
dalteparin
Date
death
defined
dependent on
detect
determine
diagnosis of SARS-CoV-2
diagnostic
Diagnostic imaging
discretion
disorder
dissemination
dose
dual
edoxaban
electrocardiogram
element
elevated
emergency room
enoxaparin
Enrollment
evaluated
exclusion criteria
expected
experimental group
fibrinogen
fondaparinux
frozen plasma
Health Organization
hemoglobin
heparin
heparin-induced thrombocytopenia
High dose
high risk
hospital
Hospital admission
hospitalised
Hospitalized
hospitalized patient
hospitalized patients
ICU
ICU admission
include
inclusion criteria
indicated
individual
inflammatory biomarkers
Informed consent
INR
intensive care
intensive care unit
Interactive Web Response System
intermediate dose
Invasive mechanical ventilation
involved
Ireland
isothermal amplification
judgement
limit
LMWH
Local
low molecular weight
low molecular weight heparin
Major
major bleeding
mechanical ventilation
Non-invasive
non-invasive positive pressure ventilation
nucleic acid
number
objective
occur
Open-label
open-label trial
outcome
oxygen
oxygen saturation
participant
Patient
patients
Phase 3
plasma
Platelet
Platelet count
Platelets
polymerase chain
polymerase chain reaction
positive pressure
positive pressure ventilation
power
Pregnancy
pressure ventilation
protocol
random
random allocation
randomised
randomised controlled trial
randomization
Randomized controlled trial
Rapid
recruited
red blood cell
renal replacement therapy
replacement therapy
response
responsible
reverse transcriptase
Reverse transcriptase polymerase chain reaction
risk
risk difference
rivaroxaban
room air
Sample size
Saudi Arabia
secondary
Secondary outcomes
Standard
standard care
status
stratified
study population
Study protocol
supplementary material
symptomatic
the patient
the United State
therapeutic anticoagulation
therapeutic dose
therapy
thrombocytopenia
Thromboembolism
Thromboprophylaxis
tinzaparin
transcriptase
transfusion
treated
Trial
Trial registration
two-sided
ULN
unfractionated heparin
United Arab Emirates
United States
Venous Thromboembolism
Ventilator-free days
Version
Warfarin
website
World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Brief videoconferencing psychological intervention for reducing COVID-19 related distress: study protocol for a randomized controlled trial
COVID-19 관련 고통을 줄이기 위한 간단한 화상회의 심리적 개입: 무작위 대조 시험을 위한 연구 프로토콜
Study Protocol
[키워드] anhedonia
Anxiety
carried
Controlled trial
COVID-19
COVID-19 pandemic
Depression
distress
Effectiveness
elevated
GHQ-12
Health Organization
imperative
include
Informed consent
intensity
outcome
platform
positive
post treatment
Primary outcome
problem
problems
Psychological
Psychological distress
Psychological intervention
Psychosocial intervention
randomised
Randomized controlled trial
reduce
reduced
reducing
reduction in
Registered
secondary
Secondary outcomes
single-blind
Social support
Stress
Study protocol
Support
Treatment
treatment as usual
Trial
Trial registration
usual care
videoconferencing
WHO
with COVID-19
World Health Organization
Worry
[DOI] 10.1186/s12889-021-10529-x PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.1186/s12889-021-10529-x PMC 바로가기 [Article Type] Study Protocol